We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-0.6%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.74B
AUM Growth
+$257M
Cap. Flow
-$141M
Cap. Flow %
-5.14%
Top 10 Hldgs %
33.17%
Holding
165
New
42
Increased
42
Reduced
15
Closed
34

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$60.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$57M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$40M
4
WBA
Walgreens Boots Alliance
WBA
+$31.6M
5
GMED icon
Globus Medical
GMED
+$26.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$102M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$40.6M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$23.8M
4
AMAG
AMAG Pharmaceuticals
AMAG
+$20.7M
5
HCA icon
HCA Healthcare
HCA
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 46.9%
2 Financials 2.94%
3 Technology 0.55%
4 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IART icon
126
Integra LifeSciences
IART
$1.47B
– –
-903,883
Closed -$17.4M
ICLR icon
127
Icon
ICLR
$12.8B
– –
-10,000
Closed -$471K
LH icon
128
Labcorp
LH
$23.1B
– –
-176,333
Closed -$15.5M
NBIX icon
129
Neurocrine Biosciences
NBIX
$17.4B
– –
-53,094
Closed -$788K
PRGO icon
130
Perrigo
PRGO
$1.47B
– –
-2,500
Closed -$364K
SNN icon
131
Smith & Nephew
SNN
$12.8B
– –
-18,750
Closed -$670K
TENX icon
132
Tenax Therapeutics
TENX
$416M
– –
-3
Closed -$446K
TXMD icon
133
TherapeuticsMD
TXMD
$24.4M
– –
-2,224
Closed -$492K
VRTX icon
134
Vertex Pharmaceuticals
VRTX
$122B
– –
-92,500
Closed -$8.76M
ZTS icon
135
CALL
Zoetis
ZTS
$31.9B
– –
-500,000
Closed -$16.1M
RVNC
136
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-256,500
Closed -$8.72M
MDRX
137
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-18,000
Closed -$289K
SPPI
138
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-159,122
Closed -$1.29M
VYNT
139
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
– –
-1,393
Closed -$2.36M
CNCE
140
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-617,649
Closed -$6.24M
GWPH
141
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-40,000
Closed -$4.29M
AMAG
142
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-999,339
Closed -$20.7M
ACHN
143
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-12,500
Closed -$95K
PETX
144
DELISTED
Aratana Therapeutics, Inc.
PETX
– –
-788,904
Closed -$12.3M
FMI
145
DELISTED
Foundation Medicine, Inc.
FMI
– –
-137,021
Closed -$3.69M
ZLTQ
146
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-1,566,155
Closed -$23.8M
NSPH
147
DELISTED
NANOSPHERE INC. COM NEW
NSPH
– –
-100,000
Closed -$3.16M
ITMN
148
CALL
DELISTED
INTERMUNE INC
ITMN
– –
-73,500
Closed -$3.25M
ITMN
149
DELISTED
INTERMUNE INC
ITMN
– –
-2,315,521
Closed -$102M
QCOR
150
CALL
DELISTED
QUESTCOR PHARMA INC
QCOR
– –
-250,000
Closed -$23.1M
3 4 5
6
7

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2014 Portfolio in Review

As of Q3 2014, Deerfield Management held 165 positions worth $2.74B, up 10% from $2.49B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Deerfield Management withdrew a net $141M in Q3 2014, closing 34 positions and reducing 15 holdings. Its most notable exit was INTERMUNE INC, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Adverum Biotechnologies worth $70M.

  • Deerfield Management's largest Q3 2014 buy was Adverum Biotechnologies: 204,768 shares worth $70M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014, an estimated $57M increase.
  • Deerfield Management's biggest Q3 2014 reduction was Keryx Biopharmaceuticals Inc, cutting an estimated $40.6M.
  • Deerfield Management fully exited INTERMUNE INC in Q3 2014, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 33% of its $2.74B portfolio in Q3 2014.
  • Deerfield Management opened 42 new positions and closed 34 in Q3 2014.
  • Deerfield Management's portfolio value rose 10% quarter-over-quarter to $2.74B.

Based on Deerfield Management's 13F filing for Q3 2014, filed 14 Nov 2014.